Rho Federal Systems Division, Inc. NIAID DAIT SACCC

 描述（由申请人提供）：通过本资助机会公告，NIAID过敏，免疫学和移植部（DAIT）打算将其对多个独立统计和临床协调中心（SACCC）的资助合并为一个单一的多组件合作协议，大概是为了降低成本，提高效率和标准化。这个新项目将资助一个SACC或中心，以支持DAIT在哮喘和过敏性疾病，自身免疫性疾病和移植领域的研究。由于Rho目前是许多这些联盟的SACCC，并且这些SACCC已经共享一些资源和流程，因此Rho非常适合提供统一的支持。 该中心的目标是提供以下服务的出色和有效的协调：方案制定，研究启动和管理，统计设计和分析，临床研究中心监测，辅助服务，数据管理，安全监督和生物信息学。为了实现这些目标，Rho旨在（1）提供在DAIT支持的联盟进行的研究方面经验丰富的工作人员，并将这些工作人员组织在一个有效管理资源的行政结构中，以响应研究联盟和DAIT的需求，并促进沟通和合作;（2）提供经验丰富的科学家和统计学家，他们与临床研究者和DAIT合作， （3）通过专门的方案团队促进方案和方案相关文件的初步和后续草案的制定、审查和修订;（4）提供研究启动和研究管理功能，以确保研究的有效性、有效性和道德性;（5）为临床研究中心的监测提供高质量和完善的程序和人员;（6）对样本采集和分发进行有效和准确的跟踪和核对;（7）提供高质量、集成和安全的信息管理系统和程序，用于收集临床和机械数据;（8）通过提供高质量的严重不良事件（SAE）报告和数据与安全监测委员会（DSMB）报告，帮助确保患者安全;和（9）提供工具，基础设施，并在规划，实施，分析和传播高维机制研究的分析支持。 基于我们在协调临床研究各个方面的丰富经验，我们计划利用我们现有的技术基础设施，结合新的创新技术：简化和自动化流程;为DAIT、临床研究者和其他关键研究利益相关者提供轻松访问数据的机会;允许中心人员配置和资源共享的灵活性;跨疾病组和集中组标准化流程和方法;并继续提供必要的灵活性，以满足这一动态研究计划不断变化的需求。

 DESCRIPTION (provided by applicant): Through this Funding Opportunity Announcement, the NIAID Division of Allergy, Immunology and Transplantation (DAIT) intends to consolidate its funding for multiple, independent Statistical and Clinical Coordinating Centers (SACCCs) into a single multi-component cooperative agreement, presumably to reduce costs and increase efficiency and standardization across research consortia. This new program will fund a single SACCC, or Center, to support DAIT research in the areas of asthma and allergic diseases, autoimmune diseases, and transplantation. Because Rho is currently the SACCC for many of these consortia and these SACCCs already share some resources and processes, Rho is well suited to provide consolidated support. The objective of the Center is to provide excellent and efficient coordination of the following services: protocol development, study initiation and management, statistical design and analysis, clinical site monitoring, ancillary services, data management, safety oversight, and bioinformatics. To accomplish these objectives, Rho aims to (1) provide staff experienced in research conducted by DAIT-supported consortia and to organize these staff in an administrative structure that manages resources efficiently, is responsive to the needs of the research consortia and DAIT, and facilitates communication and collaboration; (2) provide experienced scientists and statisticians who, in collaboration with clinical investigators and DAIT officials, design and analyze studies across the full scope of research; (3) facilitate the development, review, and revision of initial and successive drafts of protocols and protocol-related documents through dedicated protocol teams; (4) provide study initiation and study management functions that are required for the efficient, valid, and ethical conduct of studies; (5) provide high-quality and well-developed procedures and personnel for the monitoring of clinical sites; (6) provide the efficient and accurate tracking and reconciliation of specimen collection and distribution; (7) provide high-quality, integrated, and secure information management systems and procedures for the collection of clinical and mechanistic data; (8) help ensure patient safety by providing high-quality serious adverse event (SAE) reporting and Data and Safety Monitoring Board (DSMB) reports; and (9) provide tools, infrastructure, and analytical support in the planning, implementation, analysis, and dissemination of high dimensional mechanistic studies. Based on our substantial experience coordinating all aspects of clinical research, we plan to use our current technology infrastructure, combined with new and innovative techniques to: streamline and automate processes; provide easy access to data for DAIT, clinical investigators, and other key research stakeholders; allow for flexibility of Center staffing and resource sharing; standardize processes and methodologies across disease groups and centralized groups; and continue to provide the flexibility necessity to meet the changing demands of this dynamic research program.